Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A comparison of intravenous salbutamol and aminophylline in the management of acute severe asthma in children
ISRCTN ISRCTN65396765
ClinicalTrials.gov identifier
Public title A comparison of intravenous salbutamol and aminophylline in the management of acute severe asthma in children
Scientific title
Acronym N/A
Serial number at source RDC01664
Study hypothesis To determine whether a bolus of intravenous salbutamol or an aminophylline infusion is the most effective therapy for children with acute severe asthma.
Lay summary
Ethics approval The study was approved by the Thames Multicentre Research ethics committee and the local ethics committees.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Asthma
Participants - inclusion criteria 1. Age 1 to 15 years
2. Acute severe asthma with an asthma severity score of greater than 7
3. Poor response to 3 "back to back" salbutamol/ipratropium nebulisers with an improvement in asthma severity score of less than 2
Participants - exclusion criteria 1. A life threatening exacerbation
2. An underlying respiratory disease other than asthma
3. Cardiac disease
4. Treatment with a medication that alters the metabolism of aminophylline
Anticipated start date 10/01/2000
Anticipated end date 10/01/2002
Status of trial Completed
Patient information material
Target number of participants 44
Interventions 1. Bolus of intravenous salbutamol
2. Aminophylline infusion
Primary outcome measure(s) Duration of the need for supplementary oxygen to maintain saturations of above 91%.
Secondary outcome measure(s) Other end points:
1. Asthma severity score two hours after starting intravenous therapy
2. Time to stopping intravenous therapy
3. Time to decision to discharge subject
Sources of funding NHS Executive London (UK)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/12668792
Contact name Dr  Alex  Habel
  Address West Middlesex Hospital
  City/town Isleworth
  Zip/Postcode TW7 6AF
  Country United Kingdom
Sponsor NHS R&D Regional Programme Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 23/01/2004
Last edited 22/02/2008
Date ISRCTN assigned 23/01/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central